Results 151 to 160 of about 49,721 (234)

Essential Updates 2024–2025: Surgical Strategy for Esophageal Cancer Toward a New Paradigm in the Era of Immunotherapy and Personalization

Annals of Gastroenterological Surgery, Volume 10, Issue 5, Page 1368-1381, September 2026.
This review summarizes key advances from 2024 to 2025 that are reshaping esophageal cancer surgery toward a strategy‐oriented, personalized paradigm through the integration of immunotherapy, population aging, and intelligent technologies. Adjuvant nivolumab after neoadjuvant chemoradiotherapy remains the only perioperative approach with durable benefit,
Shuichiro Oya, Koichi Yagi, Yoshifumi Baba   +2 more
wiley   +1 more source

Natural Compounds Targeting Oncogenic Signaling Networks in Glioblastoma: Molecular Mechanisms, Translational Advances, and Clinical Perspectives

Brain and Behavior, Volume 16, Issue 9, September 2026.
Glioblastoma (GBM) is a highly aggressive brain tumor with a poor prognosis, driven by abnormal signaling pathways that promote growth and resistance to treatment. Conventional therapies are inadequate, highlighting the need for novel multitargeted approaches.
Mehrukh Zehravi, Md Abul Hassan, Md. Al Amin, Sherouk Hussein Sweilam, Jeetendra Kumar Gupta, Ramenani Hari Babu, Pericharla Venkata Narasimha Raju, Krishna Vamsi Kandimalla, Phanindra Erukulla, Patibandla Jahnavi, Rajeshwar Vodeti, Abdul Ajeed Mohathasim Billah, Safia Obaidur Rab, Sharuk L. Khan   +13 more
wiley   +1 more source

Efficacy and Safety of First‐Line Chemotherapy With Gemcitabine Plus Nab‐Paclitaxel in Unresectable Gallbladder Cancer

Cancer Medicine, Volume 15, Issue 9, September 2026.
ABSTRACT Purpose The purpose of this study is to evaluate the efficacy and safety of nab‐paclitaxel combined with gemcitabine (AG regimen) as a first‐line chemotherapy for patients with unresectable gallbladder cancer (GBC). Materials and Methods A retrospective analysis was conducted on patients diagnosed with GBC via histological examination ...
Yue Yang, Ziyou Wu, Yidi Zhu, Yu Zhang, Zhe Zhou, Xiaoling Song, Ziyi Yang, Shilei Liu, Runfa Bao, Xuefeng Wang, Xiangsong Wu, Wei Gong   +11 more
wiley   +1 more source

Carboplatin/Nab-Paclitaxel/Pembrolizumab Regimen [PDF]

, 2020
openaire   +1 more source

Efficacy and Safety of Neoadjuvant Chemotherapy Followed by CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With HR‐Positive, HER2‐Negative Breast Cancer: A Retrospective Single‐Centre Cohort Analysis

Cancer Medicine, Volume 15, Issue 9, September 2026.
ABSTRACT Background Endocrine therapy with CDK4/6 inhibitor has been the main treatment for HR+/HER2− breast cancer in the adjuvant setting; however, the data on the application in the neoadjuvant setting is limited. We compared neoadjuvant efficacy and safety of sequential chemotherapy‐CDK4/6 inhibitors with chemotherapy alone in HR+/HER2− breast ...
Xiaopei Dong, Fan Li, Yang Yuan, Hua Song, Yingzhe Wang, Yi Hao, Yinping Dong, Tao Wang, Li Bian, Shaohua Zhang, Jianbin Li   +10 more
wiley   +1 more source

Endophytic Fungi Natural Factories of Novel Bioactive Compounds

Chemistry &Biodiversity, Volume 23, Issue 9, September 2026.
This review provides a systematic analysis of 242 natural products isolated from 42 genera of endophytic fungi, highlighting their remarkable structural diversity and broad spectrum of biological activities . ABSTRACT Endophytic fungi represent a prolific and chemically diverse source of novel specialized metabolites with significant pharmacological ...
Dilmurod Murodullayev, Jakhongir Movlanov, Liu Wei, Wei Liu, Maksud Isokov, Santosh Kumar Bose, Fazliddin Kobilov, Zamira Djumayeva, Buston Islamov, Jamila Sherkulova, Zafar Matyakubov, Muniskhon Meylieva, Munisa Ergasheva, Diyor Abduraxmanov, Guozheng Huang, Hongchen Jiang, Kakhramon Davranov, Guohui Pan, Nigora Rustamova   +18 more
wiley   +1 more source

Reactive Oxygen Species in Breast Cancer: From Redox Dysregulation to ROS‐Responsive Therapeutics

Cell Biochemistry and Function, Volume 44, Issue 9, September 2026.
ABSTRACT Breast cancer is the most frequently diagnosed malignancy among women worldwide, with 2.3 million new cases and approximately 670,000 deaths reported in 2022 alone. Despite advances in therapy, metastasis and acquired drug resistance remain major clinical challenges.
Marija Nikolovska, Radoslav Stojchevski, Aleksandar Eftimov, Mitko Mladenov, Dimiter Avtanski, Nikola Hadzi‐Petrushev   +5 more
wiley   +1 more source

Sintilimab Combined With Albumin‐Bound Paclitaxel and SOX Regimen as Conversion Therapy for Unresectable Advanced Gastric Cancer Achieving Complete Remission: A Case Report and Literature Review

Clinical Case Reports, Volume 14, Issue 9, September 2026.
ABSTRACT For carefully selected patients with unresectable advanced gastric cancer, immunochemotherapy combining PD‐1 inhibitor with albumin‐bound paclitaxel and S‐1/oxaliplatin may achieve deep remission and enable successful R0 resection. Our findings suggest that this multimodal conversion approach could be considered in selected cases with ...
Yufan Tang, Boquan Zhou, Bingbing Wen, Ke Yu, Jiajia Jia, Ying Sha, Jixiang Liu, Luyao Li, Ruifang Fan   +8 more
wiley   +1 more source

Complete Response to Tislelizumab in an Elderly Patient With Metastatic Pulmonary Squamous Cell Carcinoma: Potential Synergy With Metformin and Multidisciplinary Management

Clinical Case Reports, Volume 14, Issue 9, September 2026.
ABSTRACT Carefully selected elderly patients with metastatic PSCC may obtain a durable complete response via tislelizumab chemoimmunotherapy combined with metformin and standardized MDT management, providing practical clinical reference for high‐risk elderly lung cancer patients complicated with multiple comorbidities.
Lei Li
wiley   +1 more source

Cisplatin/Nab-Paclitaxel/Pembrolizumab Regimen [PDF]

, 2020
openaire   +1 more source